Liquidia (LQDA) Other Accumulated Expenses (2019 - 2026)
Liquidia's (LQDA) quarterly Other Accumulated Expenses came in at $11.3 million in Q1 2026, up 119.73% year-on-year from $5.2 million in Q1 2025, and up 34.83% quarter-over-quarter from $8.4 million in Q4 2025.
Liquidia (LQDA) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Liquidia's Other Accumulated Expenses history runs 8 years deep, the most recent figure standing at $11.3 million for Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 119.73% year-over-year to $11.3 million in Q1 2026; TTM through Mar 2026 was $11.3 million, a 119.73% increase from a year earlier, with the FY2025 full-year figure at $8.4 million, up 96.65% from the prior year.
- Other Accumulated Expenses grew to $11.3 million in Q1 2026 per LQDA's latest filing, from $8.4 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $11.3 million in Q1 2026 and bottomed at $903000.0 in Q4 2022.
- The 5-year median for Other Accumulated Expenses is $4.3 million (2024), against an average of $4.3 million.
- Across the five-year window, Other Accumulated Expenses plunged 73.47% in 2023 and jumped 304.44% in 2024, its largest moves.
- Year by year, Other Accumulated Expenses stood at $903000.0 in 2022, then surged by 116.39% to $2.0 million in 2023, then soared by 118.63% to $4.3 million in 2024, then surged by 96.65% to $8.4 million in 2025, then surged by 34.83% to $11.3 million in 2026.
- Per Business Quant, the three latest LQDA Other Accumulated Expenses figures stand at $11.3 million (Q1 2026), $8.4 million (Q4 2025), and $7.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Liquidia | 7.82 Bn | 7.60 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.33 Mn |
| Dec 31, 2025 | 8.40 Mn |
| Sep 30, 2025 | 7.47 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Mar 31, 2025 | 5.16 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 2.66 Mn |
| Mar 31, 2024 | 4.64 Mn |
| Dec 31, 2023 | 1.95 Mn |
| Sep 30, 2023 | 2.38 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 1.15 Mn |
| Dec 31, 2022 | 903,000.00 |
| Sep 30, 2022 | 1.31 Mn |
| Jun 30, 2022 | 1.25 Mn |
| Mar 31, 2022 | 4.33 Mn |
| Dec 31, 2021 | 1.67 Mn |
| Sep 30, 2021 | 2.32 Mn |
| Jun 30, 2021 | 1.76 Mn |